JP Morgan Maintains Overweight on Anterix, Raises Price Target to $133

Benzinga Newsdesk www.benzinga.com Positive 81.1%

Neg 0% Neu 0% Pos 81.1%

JP Morgan analyst Sebastiano Petti maintains Anterix (NASDAQ:ATEX) with a Overweight and raises the price target from $50 to $133.